Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2016 2
2017 2
2018 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

3 results

Results by year

Filters applied: . Clear all
Page 1
Effects of Calcium-Channel Blocker Benidipine-Based Combination Therapy on Cardiac Events - Subanalysis of the COPE Trial.
Umemoto S, Ogihara T, Matsuzaki M, Rakugi H, Shimada K, Kawana M, Kario K, Ohashi Y, Saruta T; Combination Therapy of Hypertension to Prevent Cardiovascular Events (COPE) Trial Group. Umemoto S, et al. Circ J. 2018 Jan 25;82(2):457-463. doi: 10.1253/circj.CJ-17-0592. Epub 2017 Sep 2. Circ J. 2018. PMID: 28867690 Free article. Clinical Trial.
BACKGROUND: The Combination Therapy of Hypertension to Prevent Cardiovascular Events (COPE) trial was conducted to compare the effects of regimens combining the dihydropyridine calcium-channel blocker benidipine with each of 3 secondary agent types (an angiotensin-r …
BACKGROUND: The Combination Therapy of Hypertension to Prevent Cardiovascular Events (COPE) trial was conducted to compare the effect …
Effects of calcium channel blocker benidipine-based combination therapy on target blood pressure control and cardiovascular outcome: a sub-analysis of the COPE trial.
Umemoto S, Ogihara T, Matsuzaki M, Rakugi H, Ohashi Y, Saruta T; Combination Therapy of Hypertension to Prevent Cardiovascular Events (COPE) Trial Group. Umemoto S, et al. Hypertens Res. 2017 Apr;40(4):376-384. doi: 10.1038/hr.2016.158. Epub 2016 Dec 1. Hypertens Res. 2017. PMID: 27904156 Free PMC article. Clinical Trial.
We compared three benidipine-based regimens-that is, benidipine plus angiotensin receptor blocker (ARB), beta-blocker (BB) or thiazide-and found that the benidipine-BB combination was less beneficial in reducing the risk of stroke than the benidipine-thiazide combinatio …
We compared three benidipine-based regimens-that is, benidipine plus angiotensin receptor blocker (ARB), beta-blocker (BB) or thiazide-and f …
Effects of calcium channel blocker-based combinations on intra-individual blood pressure variability: post hoc analysis of the COPE trial.
Umemoto S, Ogihara T, Matsuzaki M, Rakugi H, Ohashi Y, Saruta T; Combination Therapy of Hypertension to Prevent Cardiovascular Events COPE Trial Group. Umemoto S, et al. Hypertens Res. 2016 Jan;39(1):46-53. doi: 10.1038/hr.2015.104. Epub 2015 Oct 22. Hypertens Res. 2016. PMID: 26490089 Free PMC article. Clinical Trial.
We have previously reported that the dihydropyridine calcium channel blocker benidipine combined with a beta-blocker appeared to be less beneficial in reducing the risk of stroke than a combination of benidipine and thiazide. ...The maximum BPs did not differ among …
We have previously reported that the dihydropyridine calcium channel blocker benidipine combined with a beta-blocker appeared to be l …